文献速递眼底病与葡萄膜炎

SOCS1模拟肽在小鼠糖尿病视网膜病变中的神经保护与抗炎作用

Neuroprotective and Anti-Inflammatory Effects of SOCS1 Mimetic Peptides in Mouse Diabetic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究在2型糖尿病db/db小鼠模型中,通过腹腔注射SOCS1模拟肽MiS1共7周,并与JAK1/2抑制剂巴瑞替尼对比。结果显示MiS1和巴瑞替尼均显著减轻视网膜变薄,MiS1使视网膜厚度维持在非糖尿病对照水平;两者均部分保留视网膜神经节细胞并改善小胶质细胞形态,但仅巴瑞替尼组RGC数量增加具统计学显著性。

要点

  • MiS1腹腔注射7周可减轻db/db小鼠视网膜变薄,厚度接近非糖尿病对照。
  • MiS1与巴瑞替尼均改善小胶质细胞形态,主要增加其分支面积。
  • 仅巴瑞替尼组RGC数量较未治疗db/db小鼠增加达统计学显著。

核心结论

  • 全身给予SOCS1模拟肽MiS1在实验性糖尿病视网膜病变中表现出视网膜厚度保护和小胶质细胞重塑的一致保护作用。

研究设计与样本

  • 研究使用雄性db/db小鼠(2型糖尿病模型),腹腔注射MiS1治疗7周,并与JAK1/2抑制剂巴瑞替尼治疗组、未治疗db/db组及非糖尿病db/m同窝对照比较。
  • 视网膜结构通过光学相干断层扫描在体评估,视网膜铺片用免疫组化分析Brn3a阳性视网膜神经节细胞存活和Iba1阳性小胶质细胞活化。

主要发现

  • 未治疗db/db小鼠出现视网膜变薄、视网膜神经节细胞丢失和明显的Iba1阳性小胶质细胞活化。
  • MiS1和巴瑞替尼均显著减轻视网膜变薄,MiS1使视网膜厚度维持在与非糖尿病对照相当的水平。
  • 两种治疗组视网膜神经节细胞数量均部分保留,但与未治疗db/db小鼠相比仅巴瑞替尼组增加达统计学显著性。
  • 两种治疗均改善小胶质细胞形态,主要表现为增加分支面积,而对Iba1阳性细胞数量的影响呈层和参数依赖性。

临床怎么用

  • 结果提示基于SOCS1的疗法可作为糖尿病视网膜病变的潜在治疗策略,但尚需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the therapeutic potential of a suppressor of cytokine signaling 1 (SOCS1) mimetic peptide (MiS1) via systemic administration in a mouse model of diabetic retinopathy (DR). METHODS: Male db/db mice, a model of type 2 diabetes, were treated for 7 weeks with intraperitoneal injections of MiS1. In comparison, a group of animals received the Janus kinase (JAK)1/2 inhibitor baricitinib. Untreated diabetic db/db mice and non-diabetic db/m littermates served as controls. Retinal structure was assessed in vivo by optical coherence tomography. Retinal ganglion cell (RGC) survival (Brn3a+ cells) and Iba1-positive microglial activation (Iba1+ cells) were analyzed by immunohistochemistry in retinal wholemounts. RESULTS: Untreated db/db mice exhibited retinal thinning, RGC loss, and marked Iba1+ microglial activation. Both MiS1 and baricitinib treatments significantly attenuated retinal thinning, with MiS1 preserving retinal thickness at levels comparable to those of nondiabetic controls. RGC numbers were partially preserved in both treated groups, although the increase compared with untreated db/db mice reached statistical significance only in baricitinib-treated animals. Both treatments improved microglial morphology, mainly by increasing arbor area, whereas their effects on Iba1+ cell numbers were layer and parameter dependent. CONCLUSIONS: Systemic administration of the SOCS1 mimetic peptide MiS1 showed a consistent protective profile on retinal thickness preservation and microglial remodeling in experimental DR. These findings support SOCS1-based therapies as a promising therapeutic strategy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Salobrar-García E, Opazo-Ríos L, Matamoros JA, et al. Neuroprotective and Anti-Inflammatory Effects of SOCS1 Mimetic Peptides in Mouse Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2026. PMID: 42872951. doi:10.1167/iovs.67.12.21

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。